Ngenla

Before taking this medicine

Do not use Ngenla if you: • Are critically ill following open-heart surgery, abdominal surgery or multiple accidental injuries, or have acute respiratory failure. • Are allergic to somatrogon-ghla or any other ingredient in Ngenla. • Have closed growth plates. • Have active cancer. • Have active proliferative or severe non-proliferative diabetic retinopathy. • Have Prader-Willi syndrome and are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe breathing impairment. Extra caution and monitoring are needed if you have a pre-existing tumor, a history of childhood cancer, diabetes or risk factors for diabetes, low adrenal hormone levels, an underactive thyroid or scoliosis. A higher risk of a second tumor has been reported in childhood cancer survivors treated with somatropin, particularly meningiomas in those who received radiation to the head. Ngenla may reduce insulin sensitivity, cause fluid retention, lower cortisol levels or reveal or worsen an underactive thyroid. Blood glucose and thyroid function should be monitored, with cortisol monitoring where appropriate. Eye examinations are needed before and during treatment to check for swelling of the optic nerve. Any existing swelling must be investigated and its cause treated before starting; if it develops during treatment, Ngenla must be stopped. Seek prompt medical attention for an allergic reaction. Report a new limp, persistent hip or knee pain, or persistent severe abdominal pain, as these may indicate a hip growth-plate problem or pancreatitis. Rotate injection sites to reduce the risk of local loss of fat tissue.